A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof wherein X is N or CH Q is NR6 or O A1 and A2 are independently hydrogen or C1-6 alkyl or may together form a carbonyl group R1 and R2 are independently hydrogen, halogen, CF3, CN, OR7, OR8, NR8R9, NR8COR10, NR8S02R10, S02NR8R9, SO2R10 or C1-6 alkyl optionally and independently substituted by one or more of hydroxyl, C1-6 alkoxy, halogen or NR8 R9 R 3 is hydrogen, halogen, CF3 or OR 7 R4 is hydrogen, halogen, CF3, OR8, NR8R9, NR8COR10, NR8S02R10 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR 8 R 9 or when R3 and R4 are positioned ortho and taken together form -0(CH2)mO-, where m is 1-3 R5 is hydrogen or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR8 R9 R6 is hydrogen or C1-6 alkyl R7 is hydrogen or C1-6 alkyl optionally substituted by OR8 or NR8R9 R8 is hydrogen, C1-6 alkyl, optionally substituted by hydroxyl or C1-6 alkoxy or C1-3 alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR7, NR8R9 or OCF3 or the groups R8 and R9 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR7, S and O said 5 or 6 membered ring being optionally substituted by hydroxyl or C1-6 alkoxy or the groups R8 and R9 when they are attached to a nitrogen atom may together form an azetidinyl ring optionally substituted by hydroxyl or C1-6 alkoxy and R10 is C1-6 alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR7 and n is 1 or 2. The use of the compounds in treating amyloid disease is also disclosed.La présente invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable ou promédicament de celui-ci :où X est N ou CH Q est NR6 ou O A1 et A2 sont indépendamment un hydrogène ou un alkyle en C1-6 ou peuven
